Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Up to one-quarter of breast cancer patients suffer clinically significant depression in the year after diagnosis, which may respond to intervention. About half may be prescribed a psychotropic medication, such as a selective serotonin reuptake inhibitor (SSRI), while completing breast cancer therapy. Cytochrome P-450 2D6 (CYP2D6) metabolizes SSRIs and also metabolizes tamoxifen to more active forms. Therefore, concurrent use of SSRIs may reduce tamoxifen's effectiveness at preventing breast cancer recurrence. The SSRI citalopram has limited potency to inhibit CYP2D6 activity, so has been recommended for breast cancer patients taking tamoxifen. This study provides epidemiologic evidence to support this recommendation. MATERIAL AND METHODS: We conducted a case-control study of breast cancer recurrence nested in the population of female residents of Denmark who were diagnosed with non-metastatic estrogen-receptor positive breast cancers between 1994 and 2001 and who took tamoxifen for at least one year. We ascertained complete prescription histories by linking cases' and controls' civil registration numbers to the Danish national prescription registry. We estimated the association between SSRI use while taking tamoxifen and risk of recurrent breast cancer. RESULTS: About the same proportion of recurrent cases (37 of 366) and matched controls (35 of 366) received at least one prescription for citalopram or its s-stereoisomer while taking tamoxifen (adjusted odds ratio = 1.1, 95% confidence interval = 0.7, 1.7). Breast cancer patients taking other SSRIs were also at no increased risk of recurrence (adjusted odds ratio = 0.9, 95% confidence interval = 0.5, 1.8). DISCUSSION: Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473 · cited 1×
“One class of psychotropic medications, selective serotonin reuptake inhibitors (SSRI), may reduce both depressive symptoms and menopausal symptoms [4,5].”
BackgroundHegel, M. T., Moore, C. P., Collins, E. D., Kearing, S., Gillock, K. L., Riggs, R. L., Clay, K. F., & Ahles, T. A. (2006) · Cancer · doi:10.1002/cncr.22335 · Cited by 296 · cited 1×
“Almost all newly diagnosed breast cancer patients experience normal distress [1].”
BackgroundCoyne, J. C., Palmer, S. C., Shapiro, P. J., Thompson, R., & DeMichele, A. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2003.08.012 · Cited by 123 · cited 1×
“For example, about half of the patients in a breast cancer waiting-room sample had received psychotropic medication during their breast cancer treatment [3].”
Background
Cited by
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T., Eichelbaum, M., Schwab, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.27 · Cited by 270
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“An association has been found between the use of SSRIs and risk reduction, in some studies it is more evident than in others, of colorectal cancer [439-441], lung cancer [442] and lymphoma/leukemia [443-445]; although the use of SSRIs may stimulate the secretion of prolactin, a potential breast cancer promoter, clinic…”
ResultRiblet, N., Larson, R., Watts, B. V., & Holtzheimer, P. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.05.010 · Cited by 41
Radin, D. P., & Patel, P. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.024 · Cited by 32
Metadata
- Authors
- Lash, T. L., Cronin-Fenton, D., Ahern, T. P., Rosenberg, C. L., Lunetta, K. L., Silliman, R. A., Hamilton-Dutoit, S., Garne, J. P., Ewertz, M., Sørensen, H. T., & Pedersen, L.
- Venue
- Acta Oncologica
- Published
- 2010-01
- Volume
- 49
- Issue
- 3
- Pages
- 305-312
- ISSN
- 0284-186X (ISSN-L)
- 1651-226X
- OpenAlex
- W2167421788
- Cited by
- 90
- References
- 4
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. https://app.cochat.ai/papers/10.3109/02841860903575273
- The paper
- Lash, T. L., Cronin-Fenton, D., Ahern, T. P., Rosenberg, C. L., Lunetta, K. L., Silliman, R. A., Hamilton-Dutoit, S., Garne, J. P., Ewertz, M., Sørensen, H. T., & Pedersen, L. (2010). Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncologica. https://doi.org/10.3109/02841860903575273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.